How it works
How Much Does Immunotherapy for lung cancer Cost in Spain?
Immunotherapy for lung cancer in Spain costs from $5,000 to $17,500 on average. Final pricing depends on the specific drug used, the number of infusion cycles, and the hospital location. Patients save around 87% compared to the US, where this treatment costs $90,000 on average. Most private medical centers include oncologist consultations, nursing care, and routine laboratory monitoring in their service fees.
- Specific medication type: Costs vary significantly between drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo).
- Infusion dosage: Single sessions are often priced based on the required milligram dosage per infusion.
- Hospital network: Prices in major hubs like Barcelona and Madrid may reflect the facility's tier.
- Diagnostic monitoring: Regular PET-CT scans and blood panels during treatment cycles add 15-20% to budgets.
Bookimed Expert Insight: Choosing JCI-accredited centers in Barcelona provides access to world-class oncology leaders like Dr. Enriqueta Felip. These top-tier facilities, such as Centro Médico Teknon, combine high volume—handling 23,500 operations annually—with elite credentials. While basic immunotherapy starts at lower price points, the real value in Spain lies in integrated care. Large networks like HM Hospitals offer specialized radiotherapy units that complement immunotherapy for better outcomes.
| Turkey | Austria | Spain | |
|---|---|---|---|
| Immunotherapy for lung cancer | from $8,000 | ≈ $5,800 | from $5,000 |
Discover the Best Immunotherapy for lung cancer Clinics in Spain: 4 Verified Options and Prices
Hospital HM Nou Delfos
Joan Albanell Mestres



GenesisCare Clinics
Immunotherapy for lung cancer Overview in Spain
- Biological therapy - from $900This therapy uses living organisms to treat disease by stimulating the body"s own immune system.
- Immunotherapy - from $3,500This therapy boosts the body"s natural defenses to fight diseases like cancer, bringing less side effects.
- Immunotherapy with Keytruda (Pembolizumab) - from $13,500The therapy is a treatment enhancing the body"s immune system to fight cancer, using a drug highly targeted and effective.
- Immunotherapy for prostate cancer - from $6,000This therapy boosts the body"s immune system to fight against prostate cancer, offering a targeted, typically well-tolerated treatment.
- Immunotherapy for lung cancer - from $5,000This therapy boosts your body"s natural defenses to fight lung cancer, using substances made by the body itself.
- Immunotherapy for breast cancer - from $2,200This therapy boosts your immune system to fight and eradicate breast cancer cells effectively.
- Immunotherapy for kidney cancer - from $2,200This therapy boosts the body"s natural defenses, often prolonging life in kidney cancer patients.
- Sarcoma Immunotherapy - from $6,000This therapy boosts the body"s immune system to fight cancerous tumors, offering promising, targeted treatment for sarcoma.
Day 1 - Arrival
- Arrive at the clinic and check-in at the reception.
- Meet the patient coordinator for a hospital tour.
- Settle into the patient room provided.
Day 2 - Pre-operation
- Meet with an oncologist for a detailed consultation.
- Undertake necessary medical tests, including blood work.
- Have a CT scan or PET scan if required.
- Meet with a nurse to discuss the treatment plan.
Day 3 - Immunotherapy
- Have a light meal before the procedure.
- Receive immunotherapy, which lasts about 2-3 hours.
- Rest in your room under medical supervision.
Day 4 - Post-operation
- Meet with a doctor to discuss the treatment effects.
- Stay in the hospital for observation if necessary.
Week 1 - Rehabilitation
- Start light physical activities like walking.
- Continue a healthy diet to support recovery.
Week 2 - Rehabilitation
- Return to work if feeling well.
- Continue with regular follow-up appointments.
Please keep in mind that each patient"s journey is unique and can vary. Always follow the specific advice provided by your medical team.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Carlos Vergés Roger
Dr. Vergés is a distinguished ophthalmologist with a PhD from Harvard and multiple national research awards, focusing on advanced eye care.
- Director of Ophthalmology at Dexeus University Hospital
- Specializes in cataract and neurophysiological vision mechanisms
- Recipient of the National Research Prize for tear secretion studies
- Member of the International Society of Refractive Surgery
- Published extensively in leading ophthalmology journals

Enriqueta Felip
Leading expert in immunotherapy for lung cancer – Dr. Felip integrates novel immunotherapies into treatment protocols at Hospital Quiron Barcelona.
- Current member of ESMO, ASCO, and IASLC
- Received the ESMO Women for Oncology Award in 2015
- Co-chair of the 20th WCLC Congress in Barcelona
- Professor of Medicine at Universitat de Vic

Joan Albanell Mestres
Dr. Joan Albanell Mestres is a leading oncologist at Hospital HM Nou Delfos in Barcelona. He heads the breast cancer program at HM Delfos. Dr. Albanell Mestres also directs oncology services at Mar Health Park. He conducted oncology research on telomerase in New York. His work is cited more than 9,000 times in medical literature.
- Published 120 articles in reputable scientific journals.
- Prominent member of GEICAM, CIBERONC, and the Spanish Society of Medical Oncology.
- Uses targeted therapy, immunotherapy, and hormone therapy for breast cancer.
- Practices at an EFQM-accredited clinic, a European standard for quality management.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova
FAQ about Immunotherapy for lung cancer in Spain
Is immunotherapy available and funded for lung cancer in Spain?
Immunotherapy for lung cancer is both available and funded in Spain through the National Health System (SNS). Standard checkpoint inhibitors like pembrolizumab and nivolumab are reimbursed for advanced cases. Access to pioneering mRNA therapeutic vaccines and personalized pharmacogenomic therapies is also available through Spain's extensive clinical trial network.
- Systemic coverage: The Spanish SNS funds core immunotherapy drugs based on mandatory biomarker testing results.
- Clinical trials: Spain leads Europe in clinical trials, including the BNT116 mRNA vaccine for small-cell lung cancer.
- Private access: Private clinics offer immediate immunotherapy access with costs ranging from $5,000 to $17,500.
- Leading centers: Facilities like Hospital Ruber Internacional and Centro Médico Teknon provide advanced diagnostic technologies.
- Expert specialists: Experts like Dr. Enriqueta Felip specialize in tailoring immunotherapy through pharmacogenomic research.
Bookimed Expert Insight: Spain’s oncology market is uniquely researcher-driven, with 83 clinics frequently participating in global trials. This creates a shortcut for patients seeking therapies not yet fully reimbursed by the public system. Some Barcelona hospitals even offer at-home administration programs for drugs like Keytruda to improve patient comfort.
Patient Consensus: Many patients find success by actively requesting specific biomarker testing like ALK, EGFR, and HER2. Those in advanced stages often prioritize centers that bridge the gap between standard care and ongoing research trials.
What types of immunotherapy are used for lung cancer in Spain?
Immunotherapy for lung cancer in Spain utilizes immune checkpoint inhibitors like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) to treat non-small cell and small cell lung cancer. These therapies are administered at Joint Commission International-accredited facilities in Madrid and Barcelona under Spanish Society of Medical Oncology guidelines.
- Checkpoint inhibitors: Pembrolizumab and Nivolumab target PD-1 proteins to reactivate immune responses against tumors.
- Combination therapy: Guidelines often suggest combining immunotherapy with chemotherapy for advanced stage 4 cases.
- Maintenance protocols: Patients frequently receive maintenance doses every 3 weeks for up to 2 years.
- Investigational trials: Facilities in Spain currently host global trials for BNT116 mRNA lung cancer vaccines.
Bookimed Expert Insight: Spain ranks among our top 5 destinations for oncology partly due to clinic capacity. In Barcelona, Hospital HM Nou Delfos serves 400,000 patients annually, while Centro Médico Teknon offers specialized oncology care. This high volume, combined with access to leading specialists like Dr. Enriqueta Felip, makes Spain a major hub for neoadjuvant and adjuvant immunotherapy protocols.
Patient Consensus: Patients emphasize the necessity of biomarker testing before starting treatment. The practical reality involves weekly chemotherapy for 3 months followed by maintenance sessions and regular PET scans every quarter.
Which hospitals are best for immunotherapy for lung cancer in Spain?
Spain is a top global destination for lung cancer immunotherapy, featuring JCI-accredited facilities like Hospital Ruber Internacional and Centro Médico Teknon. These centers specialize in PD-1/PD-L1 inhibitors and pharmacogenomic tailoring, often overseen by renowned oncologists like Professor Enriqueta Felip for advanced thoracic malignancies.
- Top accredited clinics: JCI-accredited facilities in Madrid and Barcelona ensure rigorous international safety standards.
- Specialized techniques: Oncology departments utilize pharmacogenomic methods to tailor immunotherapy for non-small cell lung cancer.
- Leading practitioners: Specialists like Professor Enriqueta Felip lead international lung cancer research and societies.
- Advanced technology: Clinics integrate immunotherapy with precision tools like CyberKnife and Da Vinci Xi systems.
Bookimed Expert Insight: While many seek out Madrid for its high clinic density, Barcelona clinics like Hospital HM Nou Delfos serve the highest patient volumes, exceeding 400,000 annually. This high throughput typically correlates with more robust clinical trial access for immunotherapy. Patients should verify if their insurance covers metastatic conditions before booking, as these specialized treatments range from $5,000 to $17,500.
Patient Consensus: Patients emphasize consulting official oncology rankings rather than general forums for these treatments. Many suggest prioritizing major institutions for professional oncology care while confirming financial coverage independently.
How can a foreign patient access immunotherapy treatment in Spain?
Foreign patients can access immunotherapy in Spain by enrolling in clinical trials or via private oncology networks in Madrid and Barcelona. Reputable facilities like Centro Médico Teknon and Hospital Ruber Internacional provide advanced therapies including mRNA lung cancer vaccines and combined immunotherapy-chemotherapy protocols.
- Entry points: Patients access care through private international desks or direct clinical trial site contact.
- Clinical trials: Ongoing studies like the BNT116 mRNA vaccine trial offer experimental access at 34 sites.
- Mandatory testing: Facilities require genetic and biomarker testing before confirming eligibility for specific immunotherapy drugs.
- Facility credentials: Top centers maintain Joint Commission International accreditation and rankings among Europe's best hospitals.
Bookimed Expert Insight: Spain ranks highly for oncology due to its massive patient capacity, with Hospital HM Nou Delfos alone serving 400,000 patients annually. While standard immunotherapy typically ranges from $3,500 to $18,000, choosing a high-volume Barcelona clinic often ensures faster access to the latest neoadjuvant protocols not yet available in smaller regional centers.
Patient Consensus: Success in treating metastatic cases often relies on combining immunotherapy with chemotherapy. Patients recommend completing at least 4 infusions locally before traveling to manage potential side effects like heart palpitations.
Are there clinical trials for lung cancer immunotherapy available in Spain?
Spain is a global leader in oncology research, currently hosting over 240 clinical trials for lung cancer immunotherapy. Patients have access to cutting-edge Phase I-III studies, including the pioneering BNT116 cancer vaccine trial and novel drug combinations at JCI-accredited centers in Madrid and Barcelona.
- Available trials: Over 241 active studies cover both small cell and non-small cell lung cancer.
- Innovative treatments: Spain hosts the first human trials for the BioNTech BNT116 mRNA vaccine.
- Top research hubs: Major trials operate at Hospital Ruber Internacional and Centro Médico Teknon.
- Specialized expertise: Leading oncologists like Dr. Enriqueta Felip specialize in PD-L1 response and pharmacogenomics.
Bookimed Expert Insight: While many countries offer standard immunotherapy, Spain stands out for its early-phase trial infrastructure. Clinics like Hospital Ruber Internacional and Centro Médico Teknon integrate 3-Tesla MRI and advanced diagnostics to precisely monitor trial participants. This technical edge often allows patients to access experimental protocols like BNT116 months before they reach other European markets.
Patient Consensus: Patients value that Spain is one of only seven nations hosting the phase one BNT116 vaccine trial. Many emphasize verifying specific trial eligibility, as doctors strictly require PD-L1 expression testing before enrollment.











